FRESENIUS HAS BEEN DEAD MONEY FOR TOO LONG (BUY; 43% UPSIDE)
20/09/21 -" We used to see Fresenius (Buy, Germany) as a debt-financed acquisition-drive in the near certain business of public health. There is no such thing as healthy leverage (debt /EBITDA between 3x and ..."
Pages
55
Language
English
Published on
20/09/21
You may also be interested by these reports :
16/04/24
Drägerwerk reported softer-than-expected Q1 24 numbers, with sales declining by 2.6%. As expected, growth in the safety segment partly offset the ...
15/04/24
The FY23 reported EPS came in ahead of our expectations, as the firm more than offset the H2 23 wage inflation with very strong profit margin ...
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
09/04/24
bioMerieux has reported better-than-expected Q1 organic sales growth, with healthy growth visible across both segments. Besides this, a promising ...